Clinical Trials Logo

Clinical Trial Summary

The UV index in Mayotte and Reunion is greater than 14, eight months out of twelve. This index decreases linearly over the period from mid-April to mid-August where it can drop to reach an index of 8 in July. The inhabitants are therefore exposed to a maximum intensity of UV radiation according to the World Health Organization (WHO). The WHO recommends extreme precautions for indices greater than 11 (avoid exposure between 11 a.m. and 3 p.m. (GMT+3 hours), stay in the shade, wear a t-shirt, sunglasses, hat and sunscreen). Sun exposure is a major risk factor in the development of skin cancer, basal cell cancer, squamous cell cancer and cutaneous melanoma. It is also the cause of premature aging of the skin. Furthermore, it causes ocular complications such as the occurrence of cataracts and this without distinction of skin phenotype. There is currently no prevention campaign on the risks of sun exposure in Mayotte or Reunion for adults, while many risky behaviors are observed both in the professional field and during leisure activities. In order to better understand risk-taking and choose appropriate awareness-raising tools, it is necessary to identify the knowledge, attitudes and practices (KAP) of these populations in terms of risk of sun exposure and to measure the impact of solar prevention education actions.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05336422
Study type Interventional
Source Centre Hospitalier Universitaire de la Réunion
Contact Lucie AUZANNEAU
Phone 0262359949
Email lucie.auzanneau@chu-reunion.fr
Status Not yet recruiting
Phase N/A
Start date April 2022
Completion date January 2024

See also
  Status Clinical Trial Phase
Terminated NCT03311191 - Quantifying Skin Oxygenation Properties in Normal vs Sun Exposed Skin
Not yet recruiting NCT05316402 - Sun Exposure for Outdoor Athletes in Mayotte and Reunion Island N/A